Advertisement

Mitoxantrone in the Treatment of Acute Leukemia

  • M. A. Coccia-Portugal
  • G. Falkson
  • A. Uys
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

Mitoxantrone is an anthracenedione with structural similarities to doxorubicin [1]. Preclinical studies showed activity against a variety of experimental mouse leukemias both in vitro and in vivo, including partial activity against a subline of P388 leukemia resistant to doxorubicin [2–4]. Clinical trials with mitoxantrone in patients with relapsed and/or refractory acute leukemia have shown activity close to that seen with the anthracycline antibodies with a lower incidence of side effects [5–11]. In previously untreated patients with acute lymphatic leukemia (ALL) and acute nonlymphatic leukemia (ANLL), mitoxantrone has shown promise as a frontline treatment [11–14] or in combination with other chemotherapy agents in refractory leukemia [15–17].

Keywords

Acute Myeloid Leukemia Eastern Cooperative Oncology Group Acute Leukemia Acute Lymphatic Leukemia P388 Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zee-Cheng RKY, Cheng CC (1978) Antineoplastic agents. Structure-activity relationship study of bis (substituted amino-alkylamino) anthraquinones. J Med Chem 21: 291–294Google Scholar
  2. 2.
    Cheng CC, Zbinden G, Zee-Cheng RKY (1979) Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics. J Pharm Sci 68: 393–396PubMedCrossRefGoogle Scholar
  3. 3.
    Johnson RK, Zee-cheng RKY, Lee WW, Acton EM, Henry DW, Cheng CC (1979) Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63: 425–439PubMedGoogle Scholar
  4. 4.
    Wallace RE, Murdock KL, Angier RB, Duff FE (1979) Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis-[((2((2-hydroxyethyl) amino)ethyl)amino)]-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39: 1570–1574PubMedGoogle Scholar
  5. 5.
    Paciucci PA, Ohruma T, Cuttner J, Silver RT, Holland JF (1983) Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43: 3919–3922PubMedGoogle Scholar
  6. 6.
    Estey EH, Keating MH, McCreadie KB, Bodey GP, Freireich EJ (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67: 389–390PubMedGoogle Scholar
  7. 7.
    Prentice HG, Robbins G, Ma DDF, Ho AD (1984) Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11: 32–35PubMedGoogle Scholar
  8. 8.
    Paciucci PA, Cuttner J, Holland JF (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11: 36–40PubMedGoogle Scholar
  9. 9.
    Moore JO, Olsen GA (1984) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11: 41–46PubMedGoogle Scholar
  10. 10.
    Meyer P, Ho AD, Ehninger G, Mjaaland I, Heidemann E, Seither E (1985) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs 3: 203–206PubMedCrossRefGoogle Scholar
  11. 11.
    Vorobiof DA, Falkson G, Coccia-Portugal MA, Terblanche APS (1987) Mitoxantrone in the treatment of acute leukemia. Invest New Drugs 5: 383–388PubMedCrossRefGoogle Scholar
  12. 12.
    Van Echo DA, Schulman PN, Ferrari A, Budman D, Markus SD, Wiernik PH (1982) A phase II trial of mitoxantrone (DHAD.NSC 301739) in adult acute leukemia. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1: 132 (abstr)Google Scholar
  13. 13.
    Prentice HG, Robbins G, Ma DDF, Ho AD (1983) Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rev 10: 57–63PubMedCrossRefGoogle Scholar
  14. 14.
    Masaoka T, Shisata H, Oguma S, Nagai K, Kitani T, Horiuchi A, Yasunaga K, Yonezawa T, Kawagoe H (1985). A phase II study of mitoxantrone in acute leukemia. Invest New Drugs 3: 197–201PubMedCrossRefGoogle Scholar
  15. 15.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1986) High-dose cytosine- arabinoside and mitoxantrone in refractory acute myeloid leukemia: clinical phase I/II study. Onkologie 9: 144–146PubMedCrossRefGoogle Scholar
  16. 16.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High dose cytosine-arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744–749PubMedGoogle Scholar
  17. 17.
    Hiddemann W, Kreutzmann H, Staif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder EV, Arlin Z, Büchner T (1987) High-dose cytosine-arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14: 73–77PubMedGoogle Scholar
  18. 18.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. A. Coccia-Portugal
    • 1
  • G. Falkson
    • 1
  • A. Uys
    • 1
  1. 1.Department of Medical OncologyUniversity of PretoriaSouth Africa

Personalised recommendations